Home LiteratureArticle Details
PMID: 20631829 Published · ppublish English Journal Article

Angiogenesis and progression in human melanoma.

Dermatology research and practice ·Vol. 2010 ·2010-00-00 ·Pages 185687

Ria R, Reale A, Castrovilli A, Mangialardi G, Dammacco F, Ribatti D, Vacca A

Abstract

In tumor growth, angiogenesis, the process of new-formation of blood vessels from pre-existing ones, is uncontrolled and unlimited in time. The vascular phase is characterized by the new-formation of vascular channels that enhances tumor cell proliferation, local invasion and hematogenous metastasis. Human malignant melanoma is a highly metastatic tumor with poor prognosis, and high resistance to treatment. Parallel with progression, melanoma acquires a rich vascular network, whereas an increasing number of tumor cells express the laminin receptor, which enables their adhesion to the vascular wall, favouring tumor cell extravasation and metastases. Melanoma neovascularization has been correlated with poor prognosis, overall survival, ulceration and increased rate of relapse. Secretion of various angiogenic cytokines, i.e. VEGF-A, FGF-2, PGF-1 and -2, IL-8, and TGF-1 by melanoma cells promote the angiogenic switch and has been correlated to transition from the radial to the vertical growth phase, and to the metastatic phase. Moreover, melanoma cells overexpress alphavbeta3, alphavbeta5, alpha2beta1 and alpha5beta1 integrins and release, together with stromal cells, higher amount of metalloproteases that increasing their invasive potential and angiogenesis. Basing on these observations, different molecular targets of antiangiogenic molecules has be recognized and various antiangiogenic agents are currently in preclinical and clinical trials for melanoma.

Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Ria R
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari I-70124, Italy.
Reale A
Castrovilli A
Mangialardi G
Dammacco F
Ribatti D
Vacca A
References (69)
69 references, click to expand
  1. [Angiogenesis and tumor progression in melanoma].
    Recenti Prog Med. 2000 Nov;91(11):581-7 PMID: 11125952
  2. Angiogenesis in melanoma.
    Semin Oncol. 2007 Dec;34(6):555-65 PMID: 18083379
  3. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma.
    J Exp Clin Cancer Res. 2008 Nov 04;27:60 PMID: 18983651
  4. Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
    Science. 2002 Mar 29;295(5564):2387-92 PMID: 11923519
  5. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
    Clin Cancer Res. 2005 Jul 15;11(14):5158-66 PMID: 16033831
  6. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
    Clin Cancer Res. 2006 Sep 15;12(18):5471-80 PMID: 17000682
  7. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis.
    Cancer Sci. 2006 Dec;97(12):1327-34 PMID: 16999819
  8. The history of the angiogenic switch concept.
    Leukemia. 2007 Jan;21(1):44-52 PMID: 16990761
  9. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung.
    In Vivo. 2001 Mar-Apr;15(2):175-80 PMID: 11317524
  10. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion.
    Cancer Res. 2004 Dec 15;64(24):8924-31 PMID: 15604254
  11. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study.
    Chest. 2004 Sep;126(3):926-34 PMID: 15364775
  12. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
    Acta Oncol. 2008;47(8):1526-30 PMID: 18607876
  13. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
    J Clin Oncol. 1998 Jun;16(6):2150-6 PMID: 9626215
  14. Pathology of malignant melanoma.
    Surg Clin North Am. 1996 Dec;76(6):1223-55 PMID: 8977548
  15. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
    Cancer. 2008 Oct 15;113(8):2139-45 PMID: 18792064
  16. Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.
    BMC Med Genet. 2007 Mar 08;8:10 PMID: 17346338
  17. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
    Int J Cancer. 2000 Sep 1;87(5):716-23 PMID: 10925366
  18. Erlotinib and bevacizumab have synergistic activity against melanoma.
    Clin Cancer Res. 2009 May 15;15(10):3495-502 PMID: 19447871
  19. Integrin signaling in malignant melanoma.
    Cancer Metastasis Rev. 2005 Jun;24(2):195-222 PMID: 15986132
  20. Matrix metalloproteinases in human melanoma.
    J Invest Dermatol. 2000 Sep;115(3):337-44 PMID: 10951266
  21. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
    Pigment Cell Res. 2006 Oct;19(5):395-405 PMID: 16965268
  22. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1.
    Biochim Biophys Acta. 1997 May 27;1356(3):271-80 PMID: 9194570
  23. Novel biomarkers in malignant melanoma.
    Clin Chim Acta. 2006 May;367(1-2):28-35 PMID: 16480699
  24. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.
    Br J Cancer. 1999 May;80(5-6):733-43 PMID: 10360651
  25. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
    Ann Surg Oncol. 2007 Aug;14(8):2367-76 PMID: 17534686
  26. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth.
    Biochem Cell Biol. 1996;74(6):853-62 PMID: 9164653
  27. Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.
    Anticancer Drugs. 2007 Nov;18(10):1221-6 PMID: 17893524
  28. Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta 1.
    Cytokine. 2005 Aug 7;31(3):241-9 PMID: 15975819
  29. Extracellular matrix proteases - cytokine regulation role in cancer and pregnancy.
    Front Biosci (Landmark Ed). 2009 Jan 01;14:1571-88 PMID: 19273147
  30. Enhanced expression of vascular endothelial growth factor in metastatic melanoma.
    Br J Cancer. 1997;76(7):930-4 PMID: 9328154
  31. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
    J Clin Oncol. 2001 Jan 15;19(2):584-92 PMID: 11208854
  32. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
    Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):177-203 PMID: 12784996
  33. Role of interleukin-8 in tumor growth and metastasis of human melanoma.
    Pathobiology. 1999;67(1):12-8 PMID: 9873223
  34. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    J Pathol. 2000 Jul;191(3):245-56 PMID: 10878545
  35. Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma.
    Oncol Rep. 2005 Jul;14(1):81-4 PMID: 15944771
  36. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer.
    Exp Dermatol. 2003 Apr;12(2):109-25 PMID: 12702139
  37. Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma.
    Can J Ophthalmol. 2009 Feb;44(1):106-7 PMID: 19169330
  38. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Chemotherapy. 2009;55(4):221-7 PMID: 19451711
  39. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma.
    Eur J Cancer. 2003 Mar;39(5):666-74 PMID: 12628847
  40. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis.
    Curr Top Microbiol Immunol. 1996;213 ( Pt 1):65-80 PMID: 8814995
  41. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
    Biochim Biophys Acta. 2004 Mar 4;1654(1):79-94 PMID: 14984769
  42. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Anticancer Res. 2004 May-Jun;24(3a):1759-63 PMID: 15274352
  43. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
    Invest New Drugs. 1996;14(2):193-202 PMID: 8913840
  44. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas.
    J Pathol. 1999 Sep;189(1):66-71 PMID: 10451490
  45. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
    Cancer. 2007 Nov 15;110(10):2269-75 PMID: 17932881
  46. The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo.
    Eur J Cell Biol. 2002 Nov;81(11):599-607 PMID: 12494997
  47. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group.
    Invest New Drugs. 2002 Nov;20(4):431-7 PMID: 12448662
  48. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
    J Immunother. 2009 Jan;32(1):79-85 PMID: 19307996
  49. Vascularity in cutaneous melanoma detected by Doppler sonography and histology: correlation with tumour behaviour.
    Br J Cancer. 1989 Jan;59(1):89-91 PMID: 2667611
  50. Thalidomide in cancer.
    Biomed Pharmacother. 2002 Feb;56(1):4-12 PMID: 11905508
  51. Temozolomide for the treatment of metastatic melanoma: a systematic review.
    Oncologist. 2007 Sep;12(9):1114-23 PMID: 17914081
  52. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system.
    Med Hypotheses. 2010 Feb;74(2):360-1 PMID: 19744799
  53. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.
    Ann Surg. 1970 Nov;172(5):902-8 PMID: 5477666
  54. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase.
    J Cutan Pathol. 1997 Apr;24(4):212-8 PMID: 9138111
  55. Angiogenic and vascular modulation by extracellular matrix cleavage products.
    Curr Pharm Des. 2009;15(4):389-410 PMID: 19199966
  56. The role of the vascular phase in solid tumor growth: a historical review.
    Neoplasia. 1999 Oct;1(4):293-302 PMID: 10935483
  57. Plasminogen activation in melanocytic neoplasia.
    Cancer Res. 1994 Aug 15;54(16):4547-52 PMID: 8044805
  58. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
    Clin Cancer Res. 2003 May;9(5):1648-55 PMID: 12738717
  59. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
    Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4048-54 PMID: 15217937
  60. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor.
    Cancer. 1993 Jul 15;72(2):455-61 PMID: 7686442
  61. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
    Cancer. 2009 Jan 1;115(1):119-27 PMID: 19090009
  62. The placenta growth factor in skin angiogenesis.
    J Dermatol Sci. 2006 Jan;41(1):11-9 PMID: 16216466
  63. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
    Blood. 1999 May 1;93(9):3064-73 PMID: 10216103
  64. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
    Cancer Res. 1988 Mar 1;48(5):1270-8 PMID: 2963689
  65. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis.
    Melanoma Res. 1997 Aug;7 Suppl 2:S19-26 PMID: 9578413
  66. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study.
    Am J Pathol. 1988 Nov;133(2):419-23 PMID: 3189515
  67. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
    Microvasc Res. 2009 Mar;77(2):78-86 PMID: 18805433
  68. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74 PMID: 16736151
  69. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.
    J Clin Oncol. 2009 Nov 1;27(31):5287-97 PMID: 19738110
Article Info
Journal
Dermatology research and practice
Abbr.
Dermatol Res Pract
ISSN
1687-6113
Published
2010-00-00
Epub
2010-00-06
Pages
185687
Language
English
Region
Egypt
NLM ID
101312803
PMCID
PMC2901609
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com